Insulin dosage determination method and device and computer readable storage medium

Abstract

The invention relates to an insulin dosage determination method and device and a computer readable storage medium. The method comprises the steps of determining whether a current insulin dosage is in an abnormal state or not according to blood glucose data of a target object in a preset time period; verifying insulin parameters corresponding to the current insulin dosage under the condition that the current insulin dosage is abnormal; and adjusting the insulin parameters according to the verification result to obtain the target insulin dosage. According to the method, whether the insulin dosage is in an abnormal state or not can be accurately determined by judging the blood glucose data. Under the abnormal condition, the insulin parameter corresponding to the insulin dose is verified to accurately determine the cause of the abnormal insulin dose, so that the insulin parameter causing the abnormal insulin dose can be adjusted based on the verification result to obtain a more accurate target insulin dose; and the accuracy of determining the target insulin dosage is improved.

Description

Technical Field

[0001] The present application relates to the field of medical technology, and in particular to a method and device for determining insulin dosage and a computer-readable storage medium. Background Art

[0002] With the continuous development of medical technology, medical equipment is also moving towards intelligence.

[0003] Taking the medical device as an insulin pump as an example, the insulin dosage can be flexibly adjusted by adjusting the insulin pump parameter value. In the related art, the insulin pump parameters are mainly set according to the empirical values, and the insulin dosage is determined based on the set insulin pump parameters. For example, the insulin pump parameters include the bolus, basal rate, carbohydrate to insulin ratio (Insulin to Carbohydrate Ratio, abbreviated ICR), insulin sensitivity factor (Insulin Sensitivity Factor, abbreviated ISF), etc.

[0004] However, the insulin dosage obtained by the related art method is inaccurate. Summary of the invention

[0005] Based on this, it is necessary to provide a method, device and computer-readable storage medium for determining insulin dosage in order to solve the above technical problems, so as to accurately obtain insulin dosage.

[0006] In a first aspect, the present application provides a method for determining an insulin dosage, the method comprising: determining whether a current insulin dosage is in an abnormal state based on the blood glucose data of a target subject in a preset time period; under the condition that the current insulin dosage is abnormal, verifying the insulin parameters corresponding to the current insulin dosage; and adjusting the insulin parameters based on the verification results to obtain a target insulin dosage.

[0007] In one embodiment, the preset time period is the basal rate stage; according to the blood glucose data of the target object in the preset time period, determining whether the current insulin dose is in an abnormal state includes: obtaining the blood glucose fluctuation quantification value of the target object in the preset time period according to the blood glucose data; if the blood glucose data is within the first preset blood glucose range, and the blood glucose fluctuation quantification value is less than the preset fluctuation threshold, then determining that the current insulin dose is not in an abnormal state; if the blood glucose data is not within the first preset blood glucose range, or the blood glucose fluctuation quantification value is greater than or equal to the preset fluctuation threshold, then determining that the current insulin dose is in an abnormal state. In one embodiment, the blood glucose fluctuation quantification value is any one of the blood glucose standard deviation, blood glucose variation coefficient, maximum blood glucose fluctuation amplitude, and average blood glucose fluctuation amplitude.

[0008] In one of the embodiments, the preset time period is a large-dose stage; based on the blood glucose data of the target object in the preset time period, determining whether the current insulin dose is in an abnormal state includes: if the blood glucose data is within a second preset blood glucose range, determining that the current insulin dose is not in an abnormal state; if the blood glucose data is not within the second preset blood glucose range, determining that the current insulin dose is in an abnormal state; the second preset blood glucose range is greater than the first preset blood glucose range.

[0009] In one of the embodiments, a preset time period is a basal rate stage, and an insulin parameter corresponding to a current insulin dose is a basal rate; the insulin parameter corresponding to the current insulin dose is verified, including: when the target object meets the basal rate verification conditions, obtaining a blood glucose difference between the verified blood glucose data of the target object and a first target blood glucose data; verifying that the blood glucose data is greater than a first preset blood glucose threshold; if the absolute value of the blood glucose difference between the verified blood glucose data and the first target blood glucose data is greater than the first preset blood glucose difference threshold, determining that the basal rate verification has failed.

[0010] In one embodiment, the insulin parameters are adjusted according to the verification result to obtain the target insulin dose, including: when the basal rate verification fails, the basal rate is adjusted based on the blood glucose difference between the verified blood glucose data and the first target blood glucose data to obtain the target insulin dose.

[0011] In one of the embodiments, the preset time period is a large-dose stage, and the insulin parameters include a carbohydrate coefficient and an insulin sensitivity coefficient; the insulin parameters corresponding to the current insulin dose are verified, including: when the target object meets the large-dose verification conditions, based on the carbohydrate coefficient and the quantified value of carbohydrates, determining the supplementary insulin dose corresponding to the quantified value of carbohydrates; based on the blood glucose difference between the current blood glucose data of the target object and the second target blood glucose data, determining the correction insulin dose. When the supplementary insulin dose or the correction insulin dose acts on the target object, and the verified blood glucose data after the preset time period does not meet the preset conditions, it is determined that the carbohydrate coefficient or the insulin sensitivity coefficient verification has failed.

[0012] In one of the embodiments, when a supplemental insulin dose acts on a target object and the verified blood glucose data after a preset time period does not meet a preset condition, it is determined that the carbohydrate coefficient verification has failed, including: obtaining the absolute value of the blood glucose difference between the verified blood glucose data and the second target blood glucose data; if the absolute value is greater than a second preset blood glucose difference threshold, it is determined that the carbohydrate coefficient verification has failed.

[0013] In one embodiment, when the corrected insulin dose acts on the target object and the verified blood sugar data after a preset time period does not meet the preset conditions, it is determined that the insulin sensitivity coefficient verification has failed, including: if the verified blood sugar data is not within a second preset blood sugar range, it is determined that the insulin sensitivity coefficient verification has failed.

[0014] In one of the embodiments, insulin parameters are adjusted according to the verification results to obtain a target insulin dose, including: adjusting a carbohydrate coefficient and an insulin sensitivity coefficient according to a blood glucose difference between current blood glucose data and target blood glucose data in a large-dose phase; and determining the target insulin dose based on the adjusted carbohydrate coefficient and the adjusted insulin sensitivity coefficient.

[0015] In a second aspect, the present application also provides a device for determining an insulin dosage, which includes: a determination module, used to determine whether a current insulin dosage is in an abnormal state based on the blood glucose data of a target object in a preset time period; a verification module, used to verify the insulin parameters corresponding to the current insulin dosage when the current insulin dosage is abnormal; and an adjustment module, used to adjust the insulin parameters according to the verification results to obtain a target insulin dosage.

[0016] In a third aspect, the present application further provides a computer device, which includes a memory and a processor, wherein the memory stores a computer program, and when the processor executes the computer program, the content of any one of the embodiments of the method for determining the insulin dosage in the first aspect is implemented.

[0017] In a fourth aspect, the present application further provides a computer-readable storage medium having a computer program stored thereon, which, when executed by a processor, implements the content of any one of the embodiments of the method for determining an insulin dose in the first aspect.

[0018] In a fifth aspect, the present application further provides a computer program product, including a computer program, which, when executed by a processor, implements the content of any one of the embodiments of the method for determining the insulin dosage in the first aspect.

[0019] The above-mentioned method, device and computer-readable storage medium for determining insulin dosage determine whether the current insulin dosage is in an abnormal state according to the blood sugar data of the target object in a preset time period. Under the condition that the current insulin dosage is in an abnormal state, the insulin parameters corresponding to the current insulin dosage are verified, and the insulin parameters are adjusted according to the verification results to obtain the target insulin dosage. The method can accurately determine whether the insulin dosage is in an abnormal state by judging the blood sugar data. In the case of an abnormality, the insulin parameters corresponding to the insulin dosage are verified again to accurately determine the cause of the abnormal insulin dosage, so that the insulin parameters that cause the abnormal insulin dosage can be adjusted based on the verification results to obtain a more accurate target insulin dosage. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 A schematic diagram of an insulin dosage adjustment process according to an embodiment;

[0021] Figure 2 is a schematic diagram of a continuous blood glucose monitoring system according to an embodiment;

[0022] Figure 3 is a schematic diagram of an insulin pump according to an embodiment;

[0023] Figure 4 An application environment diagram of a method for determining insulin dosage according to an embodiment;

[0024] Figure 5 is a schematic flow chart of a method for determining insulin dosage in one embodiment;

[0025] Figure 6 is a schematic diagram of a basal rate stage and a high-dose stage in one embodiment;

[0026] Figure 7 is a schematic flow chart of a method for determining insulin dosage in one embodiment;

[0027] Figure 8 is a schematic flow chart of a method for determining insulin dosage in one embodiment;

[0028] Fig. 9 is a schematic flow chart of a method for determining insulin dosage in one embodiment;

[0029] Fig.10 is a schematic flow chart of a method for determining insulin dosage in one embodiment;

[0030] Fig.11 is a schematic flow chart of a method for determining insulin dosage in one embodiment;

[0031] Fig.12is a schematic flow chart of a method for determining insulin dosage in one embodiment;

[0032] Fig.13 A schematic diagram of adjusting the carbohydrate coefficient in one embodiment;

[0033] Fig.14 A schematic diagram of adjusting the carbohydrate coefficient in one embodiment;

[0034] Fig.15 is a schematic flow chart of a method for determining insulin dosage in one embodiment;

[0035] Fig.16 FIG. 4 is a structural block diagram of a device for determining insulin dosage in one embodiment. DETAILED DESCRIPTION

[0036] In order to make the purpose, technical solution and advantages of the present application more clearly understood, the present application is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.

[0037] Long-term failure of blood sugar data to meet standards will have a significant impact on the target subject's quality of life. Therefore, monitoring of blood sugar data is crucial for the target subject.

[0038] Figure 1 The figure is a flow chart of adjusting the insulin dosage. In the process of monitoring the blood sugar data, after obtaining the blood sugar data of the target object, the computer device can adjust the insulin dosage according to the blood sugar data, physiological parameters and insulin duration of the target object to determine the target insulin dosage. It should be noted that when the target object has insulin action in the historical time period, the historical insulin dosage should also be considered. The blood sugar data of the target object can be obtained by a blood sugar detection device, which can include a continuous blood sugar monitoring system, an insulin pump, etc. Figure 2 Schematic diagram of a continuous blood glucose monitoring system. Figure 3 A schematic diagram of an insulin pump.

[0039] The method for determining insulin dosage provided in the embodiments of the present application can be applied to Figure 4In the application environment shown. For example, the computer device may be a server, a personal computer, a laptop, a smart phone, a tablet computer, a smart mobile phone, etc. The computer device may include a processor, a memory and a network interface connected by a system bus or wirelessly. Among them, the processor of the computer device is used to provide computing and control capabilities. The memory of the computer device may include a non-volatile storage medium and an internal memory. The non-volatile storage medium stores an operating system, a computer program and a database. The internal memory provides an environment for the operation of the operating system and the computer program in the non-volatile storage medium. The database of the computer device is used to store data in the process of determining the insulin dose. The network interface of the computer device is used to communicate with an external terminal through a network connection, and the computer program is executed by the processor to implement a method for determining an insulin dose. Among them, the computer device can be implemented by an independent computer device or a computer device cluster composed of multiple computer devices. The applicant wants to explain that the memory of the computer device is not limited to the above-mentioned memory, and may also include a high-speed random access memory, a volatile solid-state memory, etc. In addition, the composition architecture of the computer device is not limited to the above-mentioned situation, and some components may also be added or omitted.

[0040] In one embodiment, Figure 5 As shown, a method for determining insulin dosage is provided, and the method is applied to Figure 1 The computer device in the example is used to illustrate, including the following steps:

[0041] S201, determining whether a current insulin dosage is in an abnormal state based on the blood sugar data of the target subject in a preset time period.

[0042] Among them, insulin is a hormone used to lower blood sugar data. For different blood sugar data, the required insulin dose is different. However, in the process of using insulin to lower blood sugar data, the target object's physical condition changes or the manual input of insulin-related parameters is wrong, which will cause the insulin dose to be in an abnormal state. It should be noted that the abnormal state of insulin dose means that the insulin dose setting is unreasonable and cannot accurately reduce blood sugar data.

[0043] In this embodiment, after the computer device obtains the blood sugar data of the target object in the preset time period, it can determine whether the blood sugar data is within the normal blood sugar range. If all the blood sugar data are within the normal blood sugar range, it means that there is no high blood sugar or low blood sugar in the preset time period, and the current insulin dose is in a normal state; if all or part of the blood sugar data are not within the normal blood sugar range, it means that there is a high blood sugar or low blood sugar in the preset time period, and at this time, it can be determined that the current insulin dose is in an abnormal state. Alternatively, the computer device can determine whether the current insulin dose is in an abnormal state based on the duration of the blood sugar data in the normal blood sugar range in all the blood sugar data. Alternatively, the computer device can determine the blood sugar fluctuation degree within the preset time period based on the blood sugar data of the target object in the preset time period. If the blood sugar fluctuation degree is large, it means that the current insulin dose is in a normal state; if the blood sugar fluctuation degree is large, it means that the current insulin dose is in an abnormal state. This embodiment does not limit the method of judging whether the current insulin dose is in an abnormal state based on blood sugar data.

[0044] S202: Under the condition that the current insulin dosage is abnormal, verify the insulin parameters corresponding to the current insulin dosage.

[0045] Among them, insulin parameters include basal rate, CIR, insulin duration and ISF. It should be noted that the insulin parameters in different time periods are different, and each time period may be in the basal rate stage or the high-dose stage. For example, for the basal rate stage, the insulin parameters corresponding to the insulin dose in the basal rate stage include the basal rate. For the high-dose stage, the insulin parameters corresponding to the insulin dose in the high-dose stage include CIR, ISF, etc. Figure 3 This is a schematic diagram of the basal rate phase and the high-dose phase. Figure 6 The AB, CD and EF segments are high-dose stages, during which blood sugar data will fluctuate greatly, and more insulin doses are needed to lower blood sugar in this stage. The other stages except the AB, CD and EF segments are basal rate stages, during which blood sugar data changes more slowly. When it is determined that the current insulin dose is under abnormal conditions, an alarm message will be output to the user through the blood sugar testing device to prompt the user to check and confirm the abnormality.

[0046] In this embodiment, when it is determined by step S201 that the current insulin dose is in an abnormal situation, the computer device can determine the stage of the preset time period, and determine the insulin parameter corresponding to the current insulin dose according to the stage corresponding to the preset time period. The computer device can verify the value of the insulin parameter corresponding to the current insulin dose by way of an experiment to determine whether the value of the insulin parameter is reasonable. If it is reasonable, it is determined that the insulin parameter corresponding to the current insulin dose has been verified; if it is unreasonable, it is determined that the insulin parameter corresponding to the current insulin dose has not been verified. Alternatively, the computer device can calculate the target value of the insulin parameter corresponding to the blood sugar data according to the mapping relationship between the blood sugar data and the insulin parameter. And based on the target value of the insulin parameter, the insulin parameter corresponding to the current insulin dose is verified.

[0047] S203, adjusting insulin parameters according to the verification result to obtain a target insulin dose.

[0048] In the present embodiment, after obtaining the verification result of the insulin parameter corresponding to the current insulin dosage through step S202, if a certain insulin parameter verification fails, then based on the mapping relationship between the insulin parameter and the blood sugar data, the insulin parameter that fails the verification is adjusted so that the adjusted insulin parameter and the blood sugar data satisfy the mapping relationship. At the same time, after the insulin parameter is adjusted, the insulin dosage corresponding to the insulin parameter will naturally change, and the computer device can determine the insulin dosage corresponding to the adjusted insulin parameter according to the mapping relationship between the insulin parameter and the insulin dosage, and determine the insulin dosage as the target insulin dosage. In the case of failure, a prompt message can be output, and the prompt message is used to prompt the user to manually adjust the basal rate.

[0049] In the above-mentioned method for determining insulin dosage, it is determined whether the current insulin dosage is in an abnormal state according to the blood sugar data of the target object in a preset time period. Under the condition that the current insulin dosage is abnormal, the insulin parameters corresponding to the current insulin dosage are verified, and the insulin parameters are adjusted according to the verification results to obtain the target insulin dosage. This method can accurately determine whether the insulin dosage is in an abnormal state by judging the blood sugar data. In the case of abnormality, the insulin parameters corresponding to the insulin dosage are verified again to accurately determine the cause of the abnormal insulin dosage, so that the insulin parameters that cause the abnormal insulin dosage can be adjusted based on the verification results to obtain a more accurate target insulin dosage.

[0050] Based on the above embodiment, the preset time period is the basic rate stage. Figure 5The relevant contents of step S201 "determining whether the current insulin dose is in an abnormal state according to the blood sugar data of the target object in the preset time period" are introduced and explained. Figure 7 As shown, as a non-limiting example, the above step S201 may include the following content:

[0051] S301, obtaining a quantitative value of blood sugar fluctuation of a target subject in a preset time period according to blood sugar data.

[0052] In this embodiment, the computer device can input the blood glucose data into a preset blood glucose fluctuation quantification value calculation model, analyze the blood glucose data through the blood glucose fluctuation quantification value calculation model, determine the blood glucose fluctuation quantification value corresponding to the blood glucose data, and determine the blood glucose fluctuation quantification value corresponding to the blood glucose data as the blood glucose fluctuation quantification value of the target object in a preset time period.

[0053] The above-mentioned blood glucose fluctuation quantitative value is any one of the standard deviation of blood glucose (Standard Deviation of Blood Glucose, abbreviated as SDBG), the coefficient of variation of blood glucose (Coefficient of Variation, abbreviated as CV), the largest amplitude of blood glucose fluctuation (Largest Amplitude of Glycemic Excursion, abbreviated as LAGE) and the mean amplitude of blood glucose fluctuation (Mean Amplitude of Glycemic Excursions, abbreviated as MAGE).

[0054] The smaller the value of the blood sugar standard deviation SDBG is, the smaller the fluctuation of blood sugar is, and the current insulin dosage is reasonable. The blood sugar standard deviation SDBG can be expressed as:

[0055]

[0056] Among them, BG is blood sugar data; is the average value of blood glucose data; N is the total number of blood glucose data in the preset time period.

[0057] The above blood sugar variation coefficient CV can be calculated by blood sugar standard deviation SDBG. The smaller the value of the blood sugar variation coefficient CV, the smaller the fluctuation of blood sugar, and the current insulin dosage is reasonable. The blood sugar variation coefficient CV can be expressed as:

[0058]

[0059] Similarly, the smaller the value of the maximum blood sugar fluctuation range, the smaller the fluctuation range of blood sugar, and the current insulin dosage is reasonable. The above maximum blood sugar fluctuation range can be expressed as:

[0060] LAGE=Gmax -G min

[0061] Among them, G max is the maximum blood sugar data; G min is the minimum blood sugar data.

[0062] The above average blood sugar fluctuation range is to first calculate the fluctuation range of blood sugar data within a preset time period, then determine the blood sugar fluctuation direction according to the fluctuation range, and then determine the average blood sugar fluctuation range based on the fluctuation direction.

[0063] S302: If the blood sugar data is within a first preset blood sugar range and the blood sugar fluctuation quantization value is less than a preset fluctuation threshold, it is determined that the current insulin dosage is not in an abnormal state.

[0064] Among them, the first preset blood sugar range refers to the range of normal blood sugar in the basal rate stage. For example, the first preset blood sugar range can be 3.9mmol / L-7.9mmol / L. When the blood sugar data is greater than 7.9mmol / L, high blood sugar will occur; when the blood sugar data is less than 3.9mmol / L, low blood sugar will occur. The larger the blood sugar fluctuation quantization value, the greater the degree of blood sugar fluctuation. At this time, the insulin dosage corresponding to the blood sugar data is set unreasonably, and the current insulin dosage is in an abnormal state.

[0065] In this embodiment, when it is determined that the blood sugar data is in the first blood sugar range and the blood sugar fluctuation quantization value is less than the preset fluctuation threshold, the blood sugar data is normal blood sugar data. At this time, it can be determined that the insulin dosage corresponding to the blood sugar data is reasonably set, that is, the current insulin dosage is not in an abnormal state.

[0066] S303: If the blood sugar data is not within the first preset blood sugar range, or the blood sugar fluctuation quantization value is greater than or equal to the preset fluctuation threshold, it is determined that the current insulin dosage is in an abnormal state.

[0067] In this embodiment, when the blood sugar data is not within the first preset blood sugar range, it means that the target subject's blood sugar data has a high blood sugar level or a low blood sugar level. Once a high blood sugar level or a low blood sugar level occurs, it can be determined that the current insulin dose is in an abnormal state. Alternatively, when the blood sugar fluctuation quantization value is greater than or equal to the preset fluctuation threshold, it means that the fluctuation degree of the blood sugar data within the preset time period is large, and the setting of the insulin dose corresponding to the blood sugar data is unreasonable. At this time, it can be determined that the current insulin dose is in an abnormal state.

[0068] In the above-mentioned method for determining insulin dosage, the target object's blood sugar fluctuation quantitative value in a preset time period is obtained based on blood sugar data; if the blood sugar data is within the first preset blood sugar range, and the blood sugar fluctuation quantitative value is less than the preset fluctuation threshold, it is determined that the current insulin dosage is not in an abnormal state; if the blood sugar data is not within the first preset blood sugar range, or the blood sugar fluctuation quantitative value is greater than or equal to the preset fluctuation threshold, it is determined that the current insulin dosage is in an abnormal state. By setting the first preset blood sugar range and the preset blood sugar fluctuation threshold in the basal rate stage, this method can more accurately analyze the blood sugar data and the blood sugar fluctuation quantitative value, thereby more accurately determining whether the current insulin dosage is in an abnormal state.

[0069] Based on the above embodiment, the preset time period is the high-dose stage. Figure 5 The relevant contents of step S201 "determining whether the current insulin dose is in an abnormal state according to the blood sugar data of the target object in the preset time period" are introduced and explained. Figure 8 As shown, as a non-limiting example, the above step S201 may include the following content:

[0070] S401: If the blood sugar data is within a second preset blood sugar range, it is determined that the current insulin dosage is not in an abnormal state.

[0071] Among them, the second preset blood sugar range refers to the range of normal blood sugar in the high-dose stage. For example, the first preset blood sugar range can be 3.9mmol / L-10mmol / L. When the blood sugar data is greater than 10mmol / L, high blood sugar will occur; when the blood sugar data is less than 3.9mmol / L, low blood sugar will occur. The second preset blood sugar range is larger than the first preset blood sugar range, which is mainly reflected in the setting of the higher blood sugar threshold. Since the blood sugar data in the high-dose stage will show a sharp rise in blood sugar, the second preset blood sugar range in the high-dose stage will be set larger to avoid normal blood sugar data being mistaken for high blood sugar.

[0072] In this embodiment, when the blood sugar data is within the second preset blood sugar range, it means that the blood sugar data of the target subject does not show a high blood sugar level or a low blood sugar level. Therefore, it can be determined that the current insulin dosage is not in an abnormal state.

[0073] S402: If the blood sugar data is not within the second preset blood sugar range, it is determined that the current insulin dosage is in an abnormal state; the second preset blood sugar range is greater than the first preset blood sugar range.

[0074] In this embodiment, when the blood sugar data is within the second preset blood sugar range, it means that the target object's blood sugar data has a high blood sugar situation or a low blood sugar situation. Once the blood sugar situation is high or low, it can be determined that the current insulin dosage is in an abnormal state.

[0075] In the above method for determining insulin dosage, if the blood sugar data is within the second preset blood sugar range, it is determined that the current insulin dosage is not in an abnormal state; if the blood sugar data is not within the second preset blood sugar range, it is determined that the current insulin dosage is in an abnormal state; the second preset blood sugar range is greater than the first preset blood sugar range. By setting the second preset blood sugar range in the large dose stage, this method can more accurately analyze the blood sugar data, thereby more accurately determining whether the current insulin dosage is in an abnormal state.

[0076] Based on the above embodiment, the preset time period is the basal rate stage, and the insulin parameter corresponding to the current insulin dose is the basal rate. Figure 5 The relevant contents of step S202 "verifying the insulin parameters corresponding to the current insulin dose" are introduced and explained. Fig. 9 As shown, as a non-limiting example, the above step S202 may include the following content:

[0077] S501, when the target object meets the basal rate verification condition, obtain the blood glucose difference between the verification blood glucose data of the target object and the first target blood glucose data; verify that the blood glucose data is greater than a first preset blood glucose threshold.

[0078] Wherein, the basal rate verification condition refers to that the parameters of the target object meet the preset conditions. The basal rate verification condition can be that the blood sugar of the target object in the historical time period is within the first preset blood sugar range, indicating that the blood sugar of the target object is normal in the historical time period, and there is no high or low blood sugar. At this time, the basal rate verification can be started. Alternatively, the basal rate verification condition can also be that the blood sugar fluctuation quantization value of the target object in the historical time period is greater than or equal to the preset fluctuation threshold, indicating that the blood sugar fluctuation of the target object in the historical time period is small, and the basal rate verification can also be started. For example, the basal rate verification condition can be that the continuous blood sugar detection device checks the blood sugar of the target object 5 hours after the last action of insulin, and then checks once every 2 hours. As long as the blood sugar data of each check is between 5.0mmol / L-7.8mmol / L, and no food has been taken in the past 3 hours, and there has been no large dose of insulin in the past 5 hours, it can be determined that the target object meets the basal rate verification condition.

[0079] The basal rate validation process can be performed on the validation subject over three 8-hour fasting intervals throughout the day. For example, the nighttime basal rate can be validated first on the validation subject, which, once adjusted, can provide an excellent guide for selecting the daytime basal rate. Nighttime glucose data that are in the normal range will avoid hypoglycemia and provide normal glucose data during the day. If a single basal rate is successfully run overnight, then start with that basal rate for the daytime basal rate; if multiple basal rates are used overnight, start with the average of those basal rates as the daytime basal rate. Another way to validate the nighttime basal rate is to review the 12-hour glucose data on the continuous glucose monitoring device in the morning for several consecutive days and then plot a 6- to 8-hour glucose trend line starting at least 5 hours after the last bolus and last meal of the previous night.

[0080] For the daytime validation process, the daytime check can be divided into two 8-hour periods completed on different days. The shorter time avoids long fasting periods and increases insulin sensitivity, which can cause the basal rate to appear lower. For example, during the first 8-hour period check, check the first half of the day, when you can skip breakfast and eat lunch; during the second check, check the second half of the day 5 hours after the breakfast bolus, or more, and 3 hours or more after the last meal. After the check is completed, skip lunch and eat dinner. It should be noted that the above validation process is not a process that must be implemented in this protocol.

[0081] In this embodiment, when the target object meets the basal rate verification condition and before the basal rate is verified, the computer device can obtain the blood glucose data of the target object within a certain time period, and use the average value of the blood glucose data as the first target blood glucose data. In the process of verifying the basal rate, the blood glucose data of the target object is sampled at a preset time interval, and the sampled blood glucose data is used as the verification blood glucose data of the target object. After obtaining the verification blood glucose data, for any sampled verification blood glucose data, the computer device can calculate the difference between the verification blood glucose data and the first target blood glucose data to determine the change of the blood glucose data during the basal rate verification process.

[0082] During the verification process, it can be set on the continuous blood glucose monitoring device that when the absolute value of the difference between the blood glucose value and the starting blood glucose value is greater than a first preset blood glucose difference threshold, a prompt message is output.

[0083] During the verification of the basal rate stage by the computer device, a first prompt message may be output, and the first prompt message is used to prompt the target object to eat during the verification of the basal rate. For example, the prompt message may be not to eat carbohydrates, but to eat a small amount of protein (nuts, cheese or boiled eggs). During the verification of the basal rate stage by the computer device, a second prompt message may be output, and the second prompt message is used to prompt to stop the basal rate verification when the blood glucose data is less than the first preset blood glucose threshold.

[0084] It should be noted that the above-mentioned eating prompt process is not a process that must be implemented in this plan.

[0085] S502: If the absolute value of the blood glucose difference between the verified blood glucose data and the first target blood glucose data is greater than the first preset blood glucose difference threshold, it is determined that the basal rate verification has failed.

[0086] In this embodiment, after obtaining the blood glucose difference value, the computer device can obtain the absolute value of the blood glucose difference value, and compare the absolute value with the first preset blood glucose difference threshold value, and determine that the basal rate verification has not passed when the absolute value of the blood glucose difference value is greater than the first preset blood glucose difference threshold value. For example, the first preset blood glucose difference threshold value can be 1.1mmol / L, indicating that when the verification blood glucose data increases or decreases by more than 1.1mmol / L compared to the first target blood glucose data, the basal rate verification has not passed.

[0087] When verifying the basal rate, during the entire basal rate verification stage, the absolute value of the blood glucose difference between each verified blood glucose data and the first target blood glucose data is compared with the first preset blood glucose difference threshold to determine whether the basal rate is verified.

[0088] In the above-mentioned method for determining insulin dosage, when the target object meets the basal rate verification condition, the blood glucose difference between the verification blood glucose data and the first target blood glucose data of the target object is obtained; the verification blood glucose data is greater than the first preset blood glucose threshold; if the absolute value of the blood glucose difference between the verification blood glucose data and the first target blood glucose data is greater than the first preset blood glucose difference threshold, it is determined that the basal rate verification has not passed. When the basal rate verification condition is met, this method can accurately verify the basal rate by calculating the blood glucose difference between the verification blood glucose data and the first target blood glucose data, and comparing the absolute value of the blood glucose difference with the first preset blood glucose difference threshold, and the obtained verification result is also more accurate.

[0089] Based on the above embodiments, this embodiment is to Figure 2The relevant contents of step S203 "adjusting insulin parameters according to the verification result to obtain the target insulin dose" are introduced and explained. As a non-limiting example, the above step S202 may include the following contents: if the basal rate verification fails, based on the blood glucose difference between the verification blood glucose data and the first target blood glucose data, the basal rate is adjusted to obtain the target insulin dose.

[0090] In this embodiment, when the basal rate in the insulin parameter is changed, it needs to be preset in the future before it can take effect. The basal rate and insulin work slowly, so the basal rate needs to be adjusted as soon as possible. Therefore, when the computer device adjusts the basal rate, it can use the historical blood sugar change data to adjust the basal rate in advance based on the blood sugar difference between the verified blood sugar data and the first target blood sugar data. It should be noted that the adjustment process of the basal rate is the adjustment of the insulin dose, so the computer device can use the adjusted basal rate as the target insulin dose. For example, the blood sugar data adjusts the basal rate 5-8 hours before a high or low reading occurs or 2 to 3 hours before the blood sugar data starts to rise or fall. From the time the basal rate is changed, the change in the basal rate will have a full impact on blood sugar until 4-5 hours later.

[0091] In the above-mentioned method for determining the insulin dosage, when the basal rate verification fails, the basal rate is adjusted based on the blood glucose difference between the verification blood glucose data and the first target blood glucose data to obtain the target insulin dosage. When the verification fails, the method can accurately adjust the basal rate based on the blood glucose difference, so that the target insulin dosage can be accurately obtained based on the adjusted basal rate.

[0092] Based on the above embodiment, the preset time period is the high-dose stage, and the insulin parameters include the carbohydrate coefficient and the insulin sensitivity coefficient. Figure 2 The relevant contents of step S202 "verifying the insulin parameters corresponding to the current insulin dose" are introduced and explained. Fig.10 As shown, as a non-limiting example, the above step S202 may include the following content:

[0093] S601, when the target subject meets the large dose verification condition, determining the supplemental insulin dose corresponding to the quantified value of carbohydrates based on the carbohydrate coefficient and the quantified value of carbohydrates.

[0094] Among them, the large-dose verification condition means that the parameters of the target object meet the large-dose verification condition. For example, the verification condition of carbohydrates in a large dose can be that the blood sugar of the target object in the historical time period is within the second preset blood sugar range, indicating that the blood sugar of the target object is normal in the historical time period, and there is no high or low blood sugar. At this time, the basal rate verification can be started. For example, when the blood sugar data of the target object is between 5.0 and 7.8 mmol / L, and has not eaten in the past 3 hours and has not had a large dose of insulin in the past 5 hours, the verification process of the carbohydrate coefficient is started.

[0095] The carbohydrate factor above refers to the number of grams of carbohydrates provided by one unit of insulin. For example, if you take 1 unit of insulin for every 8 grams of carbohydrates, the carbohydrate factor is 8.

[0096] In this embodiment, the values ​​of carbohydrate coefficients corresponding to different target objects are different. For any target object, the values ​​of carbohydrate coefficients of the target object at different times may also be different. The computer device can calculate the product between the carbohydrate coefficient of the target object and the quantified value of carbohydrates, and use the obtained product result as the supplementary insulin dose corresponding to the quantified value of carbohydrates. Among them, the carbohydrate coefficient can be calculated by the total insulin dose of the target object. The relationship between the carbohydrate coefficient and the total insulin dose can be expressed as: ICR = (500 / 450) / total insulin dose. When using rapid-acting insulin, the coefficient is 500; when using short-acting insulin, the coefficient is 450. Alternatively, the carbohydrate coefficient can also be found based on the mapping relationship between the insulin dose and the carbohydrate coefficient, and the mapping relationship between the insulin dose and the carbohydrate coefficient can be obtained through Table 1.

[0097] Table 1

[0098]

[0099] S602: Determine a correction insulin dose based on a blood glucose difference between the current blood glucose data of the target subject and the second target blood glucose data.

[0100] The verification condition of the insulin sensitivity coefficient in the large dose may be that the blood glucose data of the target subject is higher than the third preset blood glucose threshold value in the historical time period. For example, the third preset blood glucose threshold value may be 13.9 mmol / L, that is, when the blood glucose data is higher than 13.9 mmol / L, the insulin sensitivity coefficient in the large dose may be verified. The second target blood glucose data may be blood glucose data determined based on historical experience.

[0101] In this embodiment, the computer device can send a blood sugar detection instruction to the blood sugar detection device. After receiving the detection instruction, the blood sugar detection device detects the current blood sugar data of the target object and sends the detected current blood sugar data to the computer device. The computer device calculates the blood sugar difference between the detected current blood sugar data and the second target blood sugar data, and uses the product of the insulin sensitivity coefficient and the blood sugar data as the insulin dose corresponding to the blood sugar difference to obtain the corrected insulin dose. Among them, the carbohydrate coefficient can be calculated by the total insulin dose of the target object. The relationship between the insulin sensitivity coefficient and the total insulin dose can be expressed as: ISF = (1800 / 1500) / (total insulin dose × 18) total insulin dose. Alternatively, the insulin sensitivity coefficient can also be found based on the mapping relationship between the insulin dose and the insulin sensitivity coefficient, and the mapping relationship between the insulin dose and the insulin sensitivity coefficient can be obtained through Table 2.

[0102] Table 2

[0103]

[0104] S603, when the supplemental insulin dose or the corrected insulin dose acts on the target object and the verified blood sugar data after the preset time period does not meet the preset conditions, it is determined that the carbohydrate coefficient or the insulin sensitivity coefficient verification has not passed.

[0105] In this embodiment, the computer device can control the supplemental insulin dose to act on the target object, and the supplemental insulin dose reduces the blood sugar generated by carbohydrates within a preset time period. After the preset time period, the computer device can obtain the verification blood sugar data through the blood sugar detection device, and determine whether the verification blood sugar data meets the preset conditions. If the preset conditions are not met, it is determined that the carbohydrate coefficient verification has not passed. In general, the value of the carbohydrate coefficient is usually set slightly higher before lunch to reduce the insulin of lunch carbohydrates. The demand for higher numbers comes from the extended 5-hour period during which the large dose of breakfast bolus will lower blood sugar, and the way insulin pumps often mistakenly stack insulin. In contrast, for those who consume most of the carbohydrates in the last meal of the day, the value of the carbohydrate coefficient for dinner is usually the same as or less than breakfast. The carbohydrate coefficient is changed as much as possible 20 to 30 minutes before the meal.

[0106] At the same time, the computer device can also control the correction insulin dose to act on the target object, and within the preset time period, the correction insulin dose reduces the current blood sugar data. After the preset time period, the computer device can obtain the verification blood sugar data through the blood sugar testing device, and determine whether the verification blood sugar data meets the preset conditions. If the preset conditions are not met, it is determined that the insulin sensitivity coefficient verification has not passed.

[0107] In the above-mentioned method for determining insulin dosage, when the target object meets the large-dose verification condition, the supplementary insulin dosage corresponding to the quantified value of carbohydrates is determined based on the carbohydrate coefficient and the quantified value of carbohydrates; the correction insulin dosage is determined based on the blood sugar difference between the current blood sugar data of the target object and the second target blood sugar data; when the supplementary insulin dosage or the correction insulin dosage acts on the target object, and the verification blood sugar data after the preset time period does not meet the preset condition, it is determined that the carbohydrate coefficient or the insulin sensitivity coefficient verification has not passed. In this method, when the target object meets the large-dose verification condition, the supplementary insulin dosage corresponding to the quantified value of carbohydrates can be accurately obtained based on the carbohydrate coefficient; and the correction insulin dosage can be accurately obtained based on the insulin sensitivity coefficient, so that it can be determined whether the verification blood sugar data after the preset time period meets the preset condition based on the supplementary insulin dosage and the correction insulin dosage, and then the carbohydrate coefficient or the insulin sensitivity coefficient can be accurately verified.

[0108] Based on the above embodiments, this embodiment is to Fig.10 The relevant contents of step S603 "When the supplemental insulin dose acts on the target object and the verified blood sugar data after the preset time period does not meet the preset conditions, it is determined that the carbohydrate coefficient verification has not passed" are introduced and explained. Fig.11 As shown, as a non-limiting example, the above step S603 may include the following content:

[0109] S701, obtaining the absolute value of the blood glucose difference between the verification blood glucose data and the second target blood glucose data.

[0110] In this embodiment, in the high-dose verification stage, after the verification blood glucose data is obtained, for any sampled verification blood glucose data, the computer device can calculate the absolute value of the difference between the verification blood glucose data and the second target blood glucose data to determine the change of the blood glucose data during the high-dose verification process.

[0111] S702: If the absolute value is greater than the second preset blood sugar difference threshold, it is determined that the carbohydrate coefficient verification has failed.

[0112] In this embodiment, after obtaining the absolute value of the blood glucose difference, the computer device may compare the absolute value with the second preset blood glucose difference threshold, and determine that the carbohydrate coefficient verification has failed when the absolute value of the blood glucose difference is greater than the second preset blood glucose difference threshold. For example, the second preset blood glucose difference may be 1.7 mmol / L, and when the verification blood glucose data is less than the second target blood glucose data, and the difference between the second target blood glucose data and the verification blood glucose data is greater than 1.7 mmol / L, the verification blood glucose data has a low blood glucose level, and the carbohydrate coefficient verification should be stopped at this time, and some carbohydrates should be ingested.

[0113] In the above method for determining the insulin dose, the absolute value of the blood glucose difference between the verification blood glucose data and the second target blood glucose data is obtained; if the absolute value is greater than the second preset blood glucose difference threshold, it is determined that the carbohydrate coefficient verification has not passed. This method can accurately determine whether the carbohydrate coefficient verification has passed by calculating the absolute value of the blood glucose difference between the blood glucose data and the second target blood glucose data, and comparing the absolute value of the blood glucose difference with the second preset blood glucose difference threshold.

[0114] Based on the above embodiments, this embodiment is to Fig.10 The relevant contents of step S603 "When the supplemental insulin dose acts on the target object and the verified blood glucose data after the preset time period does not meet the preset conditions, it is determined that the carbohydrate coefficient verification has not passed" are introduced and explained. As a non-limiting example, the above step S603 may include the following contents: if the verified blood glucose data is greater than the second preset blood glucose threshold, it is determined that the insulin sensitivity coefficient verification has not passed.

[0115] In this embodiment, for each verification blood sugar data, the computer device can determine whether the verification blood sugar data is within the second preset blood sugar range. If all the verification blood sugar data are within the second preset blood sugar range, it is determined that the insulin sensitivity coefficient verification has passed. If all the verification blood sugar data are greater than the second preset blood sugar threshold, it is determined that the insulin sensitivity coefficient verification has not passed.

[0116] It should be noted that before verifying the insulin sensitivity coefficient, the basal rate and carbohydrate coefficient have been verified and adjusted. Adjusting the basal rate and carbohydrate coefficient can improve the accuracy of the insulin sensitivity coefficient. During the verification of the insulin sensitivity coefficient, a prompt message can be output, which is used to prompt the target object to eat a small amount of protein and prohibit eating carbohydrates. For example, when the verified blood sugar data is lower than 3.9mmol / L, the blood sugar data is low, and the verification process of the sensitivity coefficient is stopped; when the verified blood sugar data continues to be above 7.2mmol / L, it is determined that the insulin sensitivity coefficient verification has failed.

[0117] In the above method for determining the insulin dosage, if the verified blood sugar data is greater than the second preset blood sugar threshold, it is determined that the insulin sensitivity coefficient verification has not passed. The method determines whether the verified blood sugar data is within the second preset blood sugar range, and according to the judgment result, it can accurately determine whether the insulin sensitivity coefficient verification has passed.

[0118] Based on the above embodiments, this embodiment is to Figure 2 The relevant contents of step S203 "adjusting insulin parameters according to the verification results to obtain the target insulin dose" are introduced and explained. Fig.12 As shown, as a non-limiting example, the above step S203 may include the following content:

[0119] S801, adjusting the carbohydrate coefficient and the insulin sensitivity coefficient according to the blood sugar difference between the current blood sugar data and the target blood sugar data in the large-dose phase.

[0120] In this embodiment, when the carbohydrate coefficient verification in the large dose phase fails, the computer device can calculate the blood glucose difference between the current blood glucose data and the target blood glucose data, and adjust the carbohydrate coefficient. At the same time, the computer device can calculate the blood glucose difference between the current blood glucose data and the target blood glucose data, and adjust the insulin sensitivity coefficient.

[0121] The carbohydrate coefficient can also be adjusted manually. The manual adjustment process of the carbohydrate coefficient is described in detail below. In the process of manually adjusting the carbohydrate coefficient, the adjustment value needs to be determined according to the carbohydrate coefficient of the target object. The relationship between the adjustment value and the carbohydrate coefficient can be shown in Table 3. If it is determined that the carbohydrate coefficient needs to be significantly increased or decreased, the basal rate and insulin sensitivity coefficient also need to change accordingly.

[0122] Table 3

[0123] Carbohydrate Factor Adjustment value <5.0g / U ±0.2~0.3g / U 5~10g / U ±0.3~0.5g / U 10~15g / U ±1.0g / U 16~24g / U ±1~2g / U

[0124] Fig.13Schematic diagram of adjusting the carbohydrate coefficient. For the A1 curve in the figure, when the absolute value of the difference between the current blood sugar data and the second target blood sugar data after 5 hours is 1.7mmol / L, the value of the carbohydrate coefficient is in the most reasonable state. Repeat the inspection and adjust the carbohydrate coefficient to obtain the most reasonable value of the carbohydrate coefficient. For the A2 curve in the figure, the target object has a blood sugar peak after eating, and the blood sugar data is normal after 5 hours. The carbohydrate coefficient at this time may be normal. In order to prevent the occurrence of a blood sugar peak after eating, the target object should be acted on at an earlier time, or the carbohydrates eaten should be converted into foods with higher protein. For the B curve in the figure, when the blood sugar data continues to decrease, the value of the carbohydrate coefficient needs to be increased. For the curve C in the figure, if the difference between the blood sugar data and the second target blood sugar data after 5 hours is greater than the second preset blood sugar difference threshold, the value of the carbohydrate coefficient is reduced. When adjusting the value of the carbohydrate coefficient, the absolute value of the difference between the adjusted blood sugar data and the second target blood sugar data is within the range of ±30mg / dL. When only carbohydrates are eaten, the effect of adjusting the carbohydrate coefficient is very good. Even slowly digested, low-glycemic-index carbohydrates can be matched with extended boluses. However, fat and protein also affect postprandial blood sugars and the effects are more variable. Alternatively, a quick way to check the carbohydrate count is to multiply the historical daily carbohydrate grams from the insulin pump by 10 to estimate the target subject's average daily calorie intake.

[0125] The insulin sensitivity coefficient can also be adjusted manually. The manual adjustment process of the insulin sensitivity coefficient is described in detail below. In the process of adjusting the insulin sensitivity coefficient, it is also necessary to determine the size of each adjustment value based on the insulin sensitivity coefficient of the target object. The relationship between the adjustment value and the size of the insulin sensitivity coefficient can be expressed in Table 4.

[0126] Table 4

[0127]

[0128] Fig.14Schematic diagram for adjusting the carbohydrate coefficient. For curve B in the figure, if the current blood sugar data is within the range of 3.9-7.2mmol / L, the insulin sensitivity coefficient is the most reasonable. Repeat the inspection and adjust the insulin sensitivity coefficient. For curve A in the figure, if the current blood sugar data is lower than 3.9mmol / L, the value of the insulin sensitivity coefficient is increased by 10%. For example, the insulin sensitivity coefficient of 1.1mmol / L / U is increased to 1.2mmol / L / U; or, the insulin sensitivity coefficient of 4.4mmol / L / U is increased to 4.9mmol / L / U, etc. If the blood sugar data only decreases after 2-3 hours, and the subsequent blood sugar data increases again, it may be necessary to adjust the value of the insulin sensitivity coefficient again. The second adjustment process is larger than the first adjustment process. For curve C in the figure, if the current blood sugar data is above 7.2mmol / L, the value of the insulin sensitivity coefficient needs to be reduced by 10% to make the correction dose larger. For example, lower the insulin sensitivity factor from 4.4mmol / L / U to 4.0mmol / L / U; or, lower the insulin sensitivity factor from 1.1mmol / L / U to 1.0mmol / L / U. If the blood glucose data is still high, the value of the insulin sensitivity factor may need to be adjusted again, and the second adjustment process is larger than the first adjustment process. Change the ISF until the high blood glucose reading is close to 100mg / dL (5.6mmol / L) when checked 2 or more times in a row after 5 hours. Repeat this check and adjust the value of the insulin sensitivity factor until the blood glucose reaches 70-130mg / dL after 5 hours.

[0129] S802, determining a target insulin dose based on the adjusted carbohydrate coefficient and the adjusted insulin sensitivity coefficient.

[0130] In this embodiment, after the adjusted carbohydrate coefficient and the adjusted insulin sensitivity coefficient are obtained, the product of the adjusted carbohydrate coefficient and the quantified value of carbohydrate is used as the target supplementary insulin dose. Also, the ratio of the blood glucose difference value to the adjusted insulin sensitivity coefficient is used as the target corrected insulin dose. The sum of the target supplementary insulin dose and the target corrected insulin dose is determined as the target insulin dose.

[0131] In the above method for determining insulin dosage, the carbohydrate coefficient and the insulin sensitivity coefficient are adjusted according to the blood sugar difference between the current blood sugar data and the target blood sugar data in the high-dose stage; the target insulin dosage is determined based on the adjusted carbohydrate coefficient and the adjusted insulin sensitivity coefficient. In the case where the carbohydrate coefficient and the insulin sensitivity coefficient in the high-dose stage are not verified, the method adjusts the carbohydrate coefficient and the insulin sensitivity coefficient based on the current blood sugar data and the target blood sugar data, so as to obtain a more accurate target insulin dosage.

[0132] As a specific embodiment of the present application, Fig.15 As shown, the method for determining the insulin dosage includes:

[0133] S901, obtaining blood sugar data of a target subject in a preset time period;

[0134] S902, for the basal rate stage, obtaining the blood sugar fluctuation quantitative value of the target subject in a preset time period according to the blood sugar data;

[0135] S903, if the blood sugar data is not within the first preset blood sugar range, or the blood sugar fluctuation quantization value is greater than or equal to the preset fluctuation threshold, it is determined that the current insulin dosage is in an abnormal state;

[0136] S904, when the target subject meets the basal rate verification condition, obtaining a blood glucose difference between the verification blood glucose data of the target subject and the first target blood glucose data;

[0137] S905, if the absolute value of the blood glucose difference between the verification blood glucose data and the first target blood glucose data is greater than the first preset blood glucose difference threshold, it is determined that the basal rate verification has failed;

[0138] S906, adjusting the basal rate based on the blood sugar difference between the verification blood sugar data and the first target blood sugar data to obtain a target insulin dose;

[0139] S907, for the large-dose stage, if the blood sugar data is not within the second preset blood sugar range, determining that the current insulin dosage is in an abnormal state;

[0140] S908, when the target subject meets the large dose verification condition, determining the supplemental insulin dose corresponding to the quantified value of carbohydrates based on the carbohydrate coefficient and the quantified value of carbohydrates;

[0141] S909, determining a correction insulin dosage based on a blood glucose difference between the current blood glucose data of the target subject and the second target blood glucose data;

[0142] S910, obtaining an absolute value of a blood glucose difference between the verification blood glucose data and the second target blood glucose data;

[0143] S911, if the absolute value is greater than the second preset blood sugar difference threshold, determining that the carbohydrate coefficient verification has failed;

[0144] S912, if the verified blood sugar data is greater than the second preset blood sugar threshold, determining that the insulin sensitivity coefficient verification has failed;

[0145] S913, adjusting the carbohydrate coefficient and the insulin sensitivity coefficient according to the blood sugar difference between the current blood sugar data and the target blood sugar data in the large-dose phase;

[0146] S914, determining a target insulin dose based on the adjusted carbohydrate factor and the adjusted insulin sensitivity factor.

[0147] It should be understood that, although the steps in the flowcharts involved in the above embodiments are displayed in sequence according to the indication of the arrows, these steps are not necessarily executed in sequence according to the order indicated by the arrows. Unless there is a clear explanation in this article, the execution of these steps is not strictly limited in order, and these steps can be executed in other orders. Moreover, at least a part of the steps in the flowcharts involved in the above embodiments may include multiple steps or multiple stages, and these steps or stages are not necessarily executed at the same time, but can be executed at different times, and the execution order of these steps or stages is not necessarily carried out in sequence, but can be executed in turn or alternately with other steps or at least a part of the steps or stages in other steps.

[0148] Based on the same inventive concept, the embodiment of the present application also provides an insulin dosage determination device for implementing the above-mentioned method for determining insulin dosage. The implementation scheme for solving the problem provided by the device is similar to the implementation scheme recorded in the above-mentioned method, so the specific limitations in the embodiments of one or more insulin dosage determination devices provided below can refer to the limitations of the insulin dosage determination method above, and will not be repeated here.

[0149] In one embodiment, Fig.16 As shown, a device for determining insulin dosage is provided, comprising: a determination module 11, a verification module 12 and an adjustment module 13, wherein:

[0150] A determination module 11 is used to determine whether the current insulin dosage is in an abnormal state according to the blood sugar data of the target subject in a preset time period;

[0151] A verification module 12, for verifying the insulin parameters corresponding to the current insulin dose when the current insulin dose is abnormal;

[0152] The adjustment module 13 is used to adjust the insulin parameters according to the verification result to obtain the target insulin dosage.

[0153] In one embodiment, the above-mentioned determination module includes: a first acquisition unit, a first determination unit, and a second determination unit, wherein:

[0154] A first acquisition unit is used to acquire a blood sugar fluctuation quantitative value of the target object in a preset time period according to the blood sugar data; wherein the blood sugar fluctuation quantitative value is any one of the blood sugar standard deviation, the blood sugar variation coefficient, the maximum blood sugar fluctuation range and the average blood sugar fluctuation range;

[0155] A first determination unit, configured to determine that the current insulin dosage is not in an abnormal state when the blood sugar data is within a first preset blood sugar range and the blood sugar fluctuation quantization value is less than a preset fluctuation threshold;

[0156] The second determination unit is used to determine that the current insulin dosage is in an abnormal state when the blood sugar data is not within the first preset blood sugar range or the blood sugar fluctuation quantization value is greater than or equal to a preset fluctuation threshold.

[0157] In one embodiment, the above-mentioned determination module further includes: a third determination unit and a fourth determination unit, wherein:

[0158] A third determining unit, configured to determine that the current insulin dosage is not in an abnormal state when the blood sugar data is within a second preset blood sugar range;

[0159] The fourth determination unit is used to determine that the current insulin dosage is in an abnormal state when the blood sugar data is not within a second preset blood sugar range; the second preset blood sugar range is greater than the first preset blood sugar range.

[0160] In one embodiment, the verification module includes: a second acquisition unit and a fifth determination unit, wherein:

[0161] A second acquisition unit is used to acquire a blood glucose difference between the verified blood glucose data of the target object and the first target blood glucose data when the target object meets the basal rate verification condition; the verified blood glucose data is greater than a first preset blood glucose threshold;

[0162] The fifth determining unit is configured to determine that the basal rate verification has failed when the absolute value of the blood glucose difference between the verified blood glucose data and the first target blood glucose data is greater than a first preset blood glucose difference threshold.

[0163] In one embodiment, the adjustment module includes a first adjustment unit, wherein:

[0164] The first adjustment unit is used to adjust the basal rate based on the blood glucose difference between the verified blood glucose data and the first target blood glucose data to obtain the target insulin dose when the basal rate verification fails.

[0165] In one embodiment, the verification module further includes: a sixth determination unit, a seventh determination unit and an eighth determination unit, wherein:

[0166] a sixth determination unit, configured to determine, when the target subject meets the large dose verification condition, a supplemental insulin dose corresponding to the quantified value of carbohydrates based on the carbohydrate coefficient and the quantified value of carbohydrates;

[0167] a seventh determination unit, configured to determine a correction insulin dosage based on a blood glucose difference between the current blood glucose data of the target subject and the second target blood glucose data;

[0168] The eighth determination unit is used to determine that the carbohydrate coefficient or the insulin sensitivity coefficient verification has failed when the supplemental insulin dose or the correction insulin dose acts on the target object and the verified blood glucose data after the preset time period does not meet the preset conditions.

[0169] In one embodiment, the eighth determination unit is further configured to obtain an absolute value of a blood glucose difference between the verification blood glucose data and the second target blood glucose data; if the absolute value is greater than a second preset blood glucose difference threshold, it is determined that the carbohydrate coefficient verification has failed.

[0170] In one embodiment, the eighth determination unit is further configured to determine that the insulin sensitivity coefficient verification has failed if the verified blood glucose data is greater than a second preset blood glucose threshold.

[0171] In one embodiment, the adjustment module includes: a second adjustment unit and a ninth determination unit, wherein:

[0172] A second adjustment unit is used to adjust the carbohydrate coefficient and the insulin sensitivity coefficient according to the blood sugar difference between the current blood sugar data and the target blood sugar data in the large-dose phase;

[0173] The ninth determination unit is used to determine the target insulin dosage based on the adjusted carbohydrate coefficient and the adjusted insulin sensitivity coefficient.

[0174] Each module in the above-mentioned device for determining insulin dosage can be implemented in whole or in part by software, hardware or a combination thereof. Each module can be embedded in or independent of a processor in a computer device in the form of hardware, or can be stored in a memory in a computer device in the form of software, so that the processor can call and execute operations corresponding to each module.

[0175] In one embodiment, a computer device is provided, including a memory and a processor, wherein a computer program is stored in the memory, and when the processor executes the computer program, the content of any one embodiment of the above-mentioned method for determining insulin dosage is implemented.

[0176] In one embodiment, a computer-readable storage medium is provided, on which a computer program is stored. When the computer program is executed by a processor, the content of any one embodiment of the above-mentioned method for determining the insulin dose is implemented.

[0177] In one embodiment, a computer program product is provided, comprising a computer program, which, when executed by a processor, implements the content of any one of the embodiments of the above-mentioned method for determining an insulin dose.

[0178] It should be noted that the user information (including but not limited to user device information, user personal information, etc.) and data (including but not limited to data used for analysis, stored data, displayed data, etc.) involved in this application are all information and data authorized by the user or fully authorized by all parties.

[0179] Those skilled in the art can understand that all or part of the processes in the above-mentioned embodiment methods can be completed by instructing the relevant hardware through a computer program, and the computer program can be stored in a non-volatile computer-readable storage medium. When the computer program is executed, it can include the processes of the embodiments of the above-mentioned methods. Among them, any reference to the memory, database or other medium used in the embodiments provided in the present application can include at least one of non-volatile and volatile memory. Non-volatile memory can include read-only memory (ROM), magnetic tape, floppy disk, flash memory, optical memory, high-density embedded non-volatile memory, resistive random access memory (ReRAM), magnetoresistive random access memory (MRAM), ferroelectric random access memory (FRAM), phase change memory (PCM), graphene memory, etc. Volatile memory can include random access memory (RAM) or external cache memory, etc. As an illustration and not limitation, RAM can be in various forms, such as static random access memory (SRAM) or dynamic random access memory (DRAM). The database involved in each embodiment provided in this application may include at least one of a relational database and a non-relational database. Non-relational databases may include distributed databases based on blockchains, etc., but are not limited to this. The processor involved in each embodiment provided in this application may be a general-purpose processor, a central processing unit, a graphics processor, a digital signal processor, a programmable logic device, a data processing logic device based on quantum computing, etc., but are not limited to this.

[0180] The technical features of the above embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0181] The above embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the present application. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the present application shall be subject to the attached claims.

Claims

1. A method for determining insulin dosage, characterized in that: The method comprises: Determine whether the current insulin dosage is in an abnormal state based on the target subject's blood sugar data during a preset time period; Under the condition that the current insulin dosage is abnormal, verifying the insulin parameter corresponding to the current insulin dosage; The insulin parameters are adjusted according to the verification results to obtain the target insulin dose.

2. The method according to claim 1, characterized in that: The preset time period is the base rate stage; The step of determining whether the current insulin dosage is in an abnormal state according to the blood sugar data of the target subject in a preset time period includes: According to the blood sugar data, obtaining a quantitative value of blood sugar fluctuation of the target subject in a preset time period; If the blood sugar data is within a first preset blood sugar range, and the blood sugar fluctuation quantization value is less than a preset fluctuation threshold, it is determined that the current insulin dosage is not in an abnormal state; If the blood sugar data is not within the first preset blood sugar range, or the blood sugar fluctuation quantization value is greater than or equal to the preset fluctuation threshold, it is determined that the current insulin dosage is in an abnormal state.

3. The method according to claim 2, characterized in that The blood sugar fluctuation quantification value is any one of the blood sugar standard deviation, the blood sugar variation coefficient, the maximum blood sugar fluctuation range and the average blood sugar fluctuation range.

4. The method according to claim 2, characterized in that: The preset time period is the high-dose stage; The step of determining whether the current insulin dosage is in an abnormal state according to the blood sugar data of the target subject in a preset time period includes: If the blood sugar data is within the second preset blood sugar range, determining that the current insulin dosage is not in an abnormal state; If the blood sugar data is not within the second preset blood sugar range, it is determined that the current insulin dosage is in an abnormal state; the second preset blood sugar range is greater than the first preset blood sugar range.

5. The method according to any one of claims 1 to 4, characterized in that: The preset time period is the basal rate stage, and the insulin parameter corresponding to the current insulin dose is the basal rate; The verifying of the insulin parameter corresponding to the current insulin dosage includes: When the target subject meets the basal rate verification condition, obtaining a blood glucose difference between the verified blood glucose data of the target subject and the first target blood glucose data; the verified blood glucose data is greater than a first preset blood glucose threshold; If the absolute value of the blood glucose difference between the verification blood glucose data and the first target blood glucose data is greater than a first preset blood glucose difference threshold, it is determined that the basal rate verification has failed.

6. The method according to claim 5, characterized in that The step of adjusting the insulin parameters according to the verification results to obtain a target insulin dose includes: In the case that the basal rate verification fails, the basal rate is adjusted based on the blood glucose difference between the verification blood glucose data and the first target blood glucose data to obtain the target insulin dose.

7. The method according to any one of claims 1 to 4, characterized in that: The preset time period is a large dose phase, and the insulin parameters include a carbohydrate coefficient and an insulin sensitivity coefficient; The verifying of the insulin parameter corresponding to the current insulin dosage includes: In the case where the target subject meets the high-dose verification condition, determining the supplemental insulin dose corresponding to the quantified value of carbohydrates based on the carbohydrate coefficient and the quantified value of carbohydrates; determining a correction insulin dose based on a blood glucose difference between the current blood glucose data of the target subject and a second target blood glucose data; When the supplemental insulin dose or the correction insulin dose acts on the target object and the verified blood sugar data after a preset time period does not meet a preset condition, it is determined that the carbohydrate coefficient or the insulin sensitivity coefficient verification has failed.

8. The method according to claim 7, characterized in that When the supplemental insulin dose acts on the target subject and the verified blood sugar data after the preset time period does not meet the preset condition, determining that the carbohydrate coefficient verification has failed includes: Acquire an absolute value of a blood glucose difference between the verification blood glucose data and the second target blood glucose data; If the absolute value is greater than a second preset blood sugar difference threshold, it is determined that the carbohydrate coefficient verification has failed.

9. The method according to claim 7, characterized in that: When the correction insulin dose acts on the target object and the verified blood sugar data after the preset time period does not meet the preset condition, determining that the insulin sensitivity coefficient verification has not passed includes: If the verified blood sugar data is greater than the second preset blood sugar threshold, it is determined that the insulin sensitivity coefficient verification has failed.

10. The method according to claim 7, characterized in that The step of adjusting the insulin parameters according to the verification results to obtain a target insulin dose includes: adjusting the carbohydrate coefficient and the insulin sensitivity coefficient according to the blood sugar difference between the current blood sugar data and the target blood sugar data in the large-dose phase; The target insulin dose is determined based on the adjusted carbohydrate factor and the adjusted insulin sensitivity factor.

11. A device for determining insulin dosage, characterized in that: The device comprises: A determination module, used to determine whether the current insulin dosage is in an abnormal state based on the target subject's blood sugar data in a preset time period; A verification module, used for verifying the insulin parameters corresponding to the current insulin dosage when the current insulin dosage is abnormal; The adjustment module is used to adjust the insulin parameters according to the verification result to obtain the target insulin dosage.

12. A computer-readable storage medium having a computer program stored thereon, characterized in that: When the computer program is executed by a processor, the steps of the method according to any one of claims 1 to 10 are implemented.

Images